FEMY - Femasys Inc. Stock Price, Fair Value and News

1.27USD-0.02 (-1.55%)Market Closed

Market Summary

USD1.27-0.02

Market Closed

-1.55%

FEMY Stock Price

View Fullscreen

FEMY RSI Chart

FEMY Valuation

Market Cap

28.2M

Price/Earnings (Trailing)

-1.89

Price/Sales (Trailing)

26.9

EV/EBITDA

-0.78

Price/Free Cashflow

-2.11

FEMY Price/Sales (Trailing)

FEMY Profitability

EBT Margin

-1357.59%

Return on Equity

-95.47%

Return on Assets

-61.14%

Free Cashflow Yield

-47.49%

FEMY Fundamentals

FEMY Revenue

Revenue (TTM)

1.0M

Rev. Growth (Yr)

-7.77%

Rev. Growth (Qtr)

27.23%

FEMY Earnings

Earnings (TTM)

-14.9M

Earnings Growth (Yr)

-22.17%

Earnings Growth (Qtr)

18.39%

Breaking Down FEMY Revenue

Last 7 days

5.0%

Last 30 days

-2.3%

Last 90 days

1.6%

Trailing 12 Months

60.8%

How does FEMY drawdown profile look like?

FEMY Financial Health

Current Ratio

8.43

FEMY Investor Care

Shares Dilution (1Y)

68.46%

Diluted EPS (TTM)

-0.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.0M	0	0	0
2023	1.2M	1.2M	1.1M	1.1M
2022	1.2M	1.1M	1.2M	1.2M
2021	1.1M	1.1M	1.1M	1.2M
2020	0	0	0	1.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Femasys Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2021	dyett john	acquired	-	-	175,635	-
Dec 15, 2021	dyett john	sold	-	-	-3,219,800	-
Dec 15, 2021	witte william benson	acquired	-	-	12,191	-
Jun 23, 2021	dyett john	bought	9,950	9.95	1,000	-
Jun 22, 2021	dyett john	acquired	-	-	3,219,790	-
Jun 22, 2021	dyett john	bought	520,000	13.00	40,000	-
Jun 22, 2021	dyett john	acquired	-	-	63,709	-
Jun 22, 2021	adams john q jr	acquired	-	-	199,938	-
Jun 22, 2021	adams john q jr	bought	520,000	13.00	40,000	-
Jun 22, 2021	uzialko edward r	bought	1,300,000	13.00	100,000	-

Which funds bought or sold FEMY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	16,232	16,232	-%
May 15, 2024	STATE STREET CORP	unchanged	-	22,810	61,487	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	877	2,364	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	1,752	4,724	-%
May 15, 2024	Tri Locum Partners LP	reduced	-15.34	12,193	47,439	0.02%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-39.34	-214	5,791	-%
May 15, 2024	Mariner, LLC	unchanged	-	10,774	29,044	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	31,000	31,000	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	30,000	82,000	-%
May 14, 2024	NORTHERN TRUST CORP	added	14.15	62,489	139,192	-%

Are Funds Buying or Selling FEMY?

Are funds buying FEMY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FEMY

No. of Funds

Unveiling Femasys Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 22, 2023	pharmacyte biotech, inc.	37.0%	12,711,864	SC 13D

Recent SEC filings of Femasys Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Apr 24, 2024	8-K	Current Report
Apr 05, 2024	S-8	Employee Benefits Plan
Apr 05, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 20, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to Femasys Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Femasys Inc. News

Latest updates

Femasys Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	27.2%	271,140	213,111	244,361	320,514	293,984	234,244	347,456	303,113	321,405	254,327	269,581	326,006	329,775	321,492	313,208	183,234
Gross Profit	-	-	-	158,175	210,045	188,864	148,785	216,005	200,760	198,730	190,015	164,178	218,379	236,733	-	222,773	127,959
Operating Expenses	-20.5%	3,645,250	4,584,332	4,239,439	3,146,007	3,230,538	3,149,147	3,273,194	2,860,723	3,081,480	2,547,751	2,415,623	2,119,454	2,063,281	-	1,787,650	1,611,592
S&GA Expenses	46.3%	300,487	205,448	70,883	128,899	244,896	336,438	90,374	63,177	68,863	120,804	43,284	21,828	22,819	-	31,010	13,384
R&D Expenses	-14.5%	1,770,731	2,071,260	2,072,830	1,527,172	1,537,439	1,271,608	1,648,160	1,472,924	1,421,063	1,053,837	1,140,577	894,868	995,022	-	995,620	888,701
EBITDA Margin	0.1%	-12.67	-12.68	-9.92	-9.06	-9.18	-8.96	-5.67	-6.05	-5.92	-5.87	-5.44	-5.61	-5.80	-5.99	-	-
Interest Expenses	132.5%	361,552	155,487	8,033	198	1,672	3,842	6,005	883	2,734	4,680	7,055	3,643	3,848	-	3,760	3,438
Income Taxes	100.0%	-	-212	4,550	-	-	1,250	4,250	-	800	3,600	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-2,360,853	-2,259,701	-1,083,059	-	-	-1,568,295	-1,485,451
EBT Margin	-2.2%	-13.58	-13.29	-10.42	-9.52	-9.66	-9.44	-6.14	-6.56	-6.43	-6.39	-6.04	-6.23	-6.44	-6.66	-	-
Net Income	18.4%	-3,599,510	-4,410,454	-3,996,905	-2,893,508	-2,946,257	-2,894,196	-2,982,843	-2,634,101	-2,883,030	-2,364,853	-2,259,701	-1,083,059	-1,830,232	-	-1,568,295	-1,485,451
Net Income Margin	-6.9%	-14.20	-13.29	-11.65	-9.80	-9.72	-9.45	-8.86	-8.83	-7.33	-6.39	-6.04	-6.24	-6.44	-6.66	-	-
Free Cashflow	-50.4%	-4,632,681	-3,080,879	-2,882,911	-2,804,135	-2,656,538	-2,961,764	-2,748,730	-2,554,565	-2,874,389	-2,366,525	-1,977,235	-2,733,211	-1,160,682	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-12.2%	24.00	28.00	15.00	14.00	14.00	17.00	20.00	23.00	26.00	29.00	31.00	34.00	8.00
Current Assets	-14.2%	20.00	23.00	10.00	12.00	11.00	14.00	17.00	20.00	23.00	26.00	28.00	31.00	4.00
Cash Equivalents	-17.9%	18.00	22.00	9.00	11.00	10.00	13.00	16.00	19.00	22.00	25.00	27.00	30.00	3.00
Inventory	45.6%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	9.3%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-6.8%	9.00	9.00	4.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	4.00
Current Liabilities	-22.8%	2.00	3.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Shareholder's Equity	-15.0%	16.00	18.00	10.00	13.00	12.00	15.00	18.00	21.00	23.00	26.00	29.00	31.00	-
Retained Earnings	-3.3%	-111	-108	-103	-99.97	-97.08	-94.13	-91.24	-88.26	-85.62	-82.74	-80.38	-78.12	-75.20
Additional Paid-In Capital	0.8%	125	124	113	111	109	109	109	109	108	108	108	108	23.00
Accumulated Depreciation	2.0%	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Shares Outstanding	2.0%	22.00	22.00	16.00	15.00	12.00	12.00	12.00	12.00	12.00	12.00	5.00	2.00	1.00
Float	-	-	-	-	7.00	-	-	-	23.00	-	-	-	53.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-50.5%	-4,568	-3,035	-2,855	-2,741	-2,647	-2,867	-2,730	-2,379	-2,754	-2,247	-1,801	-2,720	-1,160	-	-	-
Share Based Compensation	57.8%	78.00	49.00	504	65.00	57.00	67.00	52.00	62.00	44.00	29.00	33.00	58.00	72.00	-	-	-
Cashflow From Investing	-100.8%	-90.16	-44.90	-27.17	-62.95	-8.90	-93.88	-18.54	-174	-120	-118	-175	-12.51	-	-	-	-
Cashflow From Financing	-95.2%	778	16,105	870	3,348	-144	-81.95	-362	-96.65	-141	-130	-601	30,576	-144	-	-	-
Buy Backs	-	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FEMY Income Statement

2024-03-31

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended
Condensed Statements of Comprehensive Loss - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Statements of Comprehensive Loss [Abstract]
Sales	$ 271,140	$ 293,984
Cost of sales (excluding depreciation expense)	88,532	105,120
Operating expenses:
Research and development	1,770,731	1,537,439
Sales and marketing	300,487	244,896
General and administrative	1,502,804	1,315,137
Depreciation and amortization	71,228	133,066
Total operating expenses	3,645,250	3,230,538
Loss from operations	(3,462,642)	(3,041,674)
Other income (expense):
Interest income	224,684	97,089
Interest expense	(361,552)	(1,672)
Total other income (expense)	(136,868)	95,417
Net loss	(3,599,510)	(2,946,257)
Net loss attributable to common stockholders, basic	(3,599,510)	(2,946,257)
Net loss attributable to common stockholders, diluted	$ (3,599,510)	$ (2,946,257)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.17)	$ (0.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.17)	$ (0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	21,775,357	11,872,255
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	21,775,357	11,872,255

FEMY Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 17,835,968	$ 21,716,077
Accounts receivable, net	120,529	98,906
Inventory, net	971,297	667,118
Prepaid and other current assets	955,539	695,879
Total current assets	19,883,333	23,177,980
Property and equipment, at cost:
Leasehold improvements	1,212,417	1,212,417
Office equipment	47,308	47,308
Furniture and fixtures	417,654	414,303
Machinery and equipment	2,582,220	2,559,356
Construction in progress	569,723	423,077
Property and equipment, gross	4,829,322	4,656,461
Less accumulated depreciation	(3,615,405)	(3,545,422)
Net property and equipment	1,213,917	1,111,039
Long-term assets:
Lease right-of-use assets, net	2,227,561	2,380,225
Intangible assets, net of accumulated amortization	33,115	0
Other long-term assets	1,013,034	1,086,581
Total long-term assets	3,273,710	3,466,806
Total assets	24,370,960	27,755,825
Current liabilities:
Accounts payable	1,095,730	1,137,823
Accrued expenses	673,457	1,444,296
Clinical holdback - current portion	93,376	65,300
Lease liabilities - current portion	494,967	406,636
Total current liabilities	2,357,530	3,054,055
Long-term liabilities:
Clinical holdback - long-term portion	30,389	54,935
Convertible notes payable, net (including related parties)	4,472,456	4,258,179
Lease liabilities - long-term portion	1,902,991	2,036,067
Total long-term liabilities	6,405,836	6,349,181
Total liabilities	8,763,366	9,403,236
Commitments and contingencies
Stockholders' equity:
Common stock, $.001 par, 200,000,000 authorized, 22,216,570 shares issued and 22,099,347 outstanding as of March 31, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023	22,217	21,775
Treasury stock, 117,223 common shares	(60,000)	(60,000)
Warrants	2,631,838	2,787,137
Additional paid-in-capital	124,994,678	123,985,306
Accumulated deficit	(111,981,139)	(108,381,629)
Total stockholders' equity	15,607,594	18,352,589
Total liabilities and stockholders' equity	$ 24,370,960	$ 27,755,825

About Femasys Inc.

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

CEO	Ms. Kathy Lee-Sepsick
WEBSITE	femasys.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	34

Femasys Inc. Frequently Asked Questions

What is the ticker symbol for Femasys Inc.? What does FEMY stand for in stocks?

FEMY is the stock ticker symbol of Femasys Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Femasys Inc. (FEMY)?

As of Fri May 17 2024, market cap of Femasys Inc. is 28.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FEMY stock?

You can check FEMY's fair value in chart for subscribers.

What is the fair value of FEMY stock?

You can check FEMY's fair value in chart for subscribers. The fair value of Femasys Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Femasys Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FEMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Femasys Inc. a good stock to buy?

The fair value guage provides a quick view whether FEMY is over valued or under valued. Whether Femasys Inc. is cheap or expensive depends on the assumptions which impact Femasys Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FEMY.

What is Femasys Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FEMY's PE ratio (Price to Earnings) is -1.89 and Price to Sales (PS) ratio is 26.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FEMY PE ratio will change depending on the future growth rate expectations of investors.